Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: Effect of HLA disparity, ABO incompatibility, and method of T-cell depletion

被引:50
作者
Keever-Taylor, CA
Bredeson, C
Loberiza, FR
Casper, JT
Lawton, C
Rizzo, D
Burns, WH
Margolis, DA
Vesole, DH
Horowitz, M
Zhang, MJ
Juckett, M
Drobyski, WR
机构
[1] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, BMT Proc Labs, Dept Med, Milwaukee, WI 53226 USA
[2] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, BMT Proc Labs, Dept Pediat, Milwaukee, WI 53226 USA
[3] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, BMT Proc Labs, Dept Radiat Oncol, Milwaukee, WI 53226 USA
[4] Med Coll Wisconsin, Froedtert Mem Lutheran Hosp, Hlth Policy Inst, Milwaukee, WI 53226 USA
[5] Childrens Hosp Wisconsin, Milwaukee, WI 53201 USA
关键词
bone marrow transplantation; T cell depletion; graft-versus-host disease; ABO compatibility; CMV serostatus;
D O I
10.1053/bbmt.2001.v7.pm11760150
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Multivariate analysis was performed to determine the independent factors affecting the risk of acute GVHD (aGVHD) grades II to IV and extensive chronic GVHD (cGVHD) and the rate of survival in 481 recipients of T cell-depleted (TCD) marrow allografts who received transplants at a single center between 1991 and 2000. All patients received grafts partially depleted of CD3(+) T cells by complement-mediated lysis using 2 narrow-specificity monoclonal antibodies (MoAbs), T10B9.1A-31 (n = 400) or Muromonab-Orthoclone OKT3 (n = 81). Factors considered in the analysis included patient/donor sex, age, cytomegalovirus (CMV) status, and ABO blood group along with T-cell dose, disease and disease status, donor relationship, HLA antigen (Ag) mismatch (b7M), growth-factor use, anti-thymocyte globulin use, year of transplantation, and the MoAb used for TCD. The results showed an association of HLA MM with an increased relative risk (RR) of aGVHD for recipients of grafts from related donors that were greater than or equal to2 Ag MM (n = 73, RR = 2.09, P =.005), matched unrelated (UR) donors (n = 130, RR = 1.98, P = .004), and greater than or equal to2 Ag Mr I UR donors (n = 34, RR = 2.68, P = .003) compared with the baseline matched-sibling group (n = 121). INTO increased risk of aGVHD was seen for 0 to 1 Ag MM family donors (n = 24) or 1 Ag MM UR donors (n = 99). aGVHD risk was increased with minor, but not major or major-minor, ABO disparity (RR = 2.0, P =.003) compared with that of ABO-identical pairs. We found less effective TCD and resultant higher T-cell dose for recipients of grafts that were T cell depleted using OKT3. However, the use of OKT3 and not the T-cell dose was associated with increased aGVHD risk (RR of 1.84, P = .001). Increased risk of extensive cGVHD was associated with patient age of > 20 years (RR = 2.2, P < .0001) and with CMV status (positive patient/negative donor, RR = 1.9, P = .002). Decreased survival was associated with older age (> 20 years), a greater than or equal to2 Ag MM related donor, a 1 or greater than or equal to2 Ag MM UR donor, risk group, and a CMV positive patient/-negative donor pair. There was no difference in survival for 0 to 1 Ag MM related or matched UR donors compared with the baseline group. These data indicate that there are quantitative as well as potential qualitative differences in outcome depending on the TCD method. Expected and unexpected risk factors for GVHD and survival were associated with partial TCD. Our data support the consideration of ABO match in donor selection, the preferential selection of CMV positive donors for CMV-positive recipients, and the acceptance of 1 but not greater than or equal to2 Ag HLA MM donors.
引用
收藏
页码:620 / 630
页数:11
相关论文
共 69 条
[1]  
ASH RC, 1991, BONE MARROW TRANSPL, V7, P443
[2]   SUCCESSFUL ALLOGENEIC TRANSPLANTATION OF T-CELL DEPLETED BONE-MARROW FROM CLOSELY HLA-MATCHED UNRELATED DONORS [J].
ASH, RC ;
CASPER, JT ;
CHITAMBAR, CR ;
HANSEN, R ;
BUNIN, N ;
TRUITT, RL ;
LAWTON, C ;
MURRAY, K ;
HUNTER, J ;
BAXTERLOWE, LA ;
GOTTSCHALL, JL ;
OLDHAM, K ;
ANDERSON, T ;
CAMITTA, B ;
MENITOVE, J .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (08) :485-494
[3]  
ATKINSON K, 1990, BONE MARROW TRANSPL, V5, P69
[4]   Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype [J].
Aversa, F ;
Tabilio, A ;
Velardi, A ;
Cunningham, I ;
Terenzi, A ;
Falzetti, F ;
Ruggeri, L ;
Barbabietola, G ;
Aristei, C ;
Latini, P ;
Reisner, Y ;
Martelli, MF .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (17) :1186-1193
[5]   ABO COMPATIBILITY AND ACUTE GRAFT-VERSUS-HOST DISEASE FOLLOWING ALLOGENEIC BONE-MARROW TRANSPLANTATION [J].
BACIGALUPO, A ;
VANLINT, MT ;
OCCHINI, D ;
MARGIOCCO, M ;
FERRARI, G ;
PITTALUGA, PA ;
FRASSONI, F ;
PERALVO, J ;
LERCARI, G ;
CARUBIA, F ;
MARMONT, AM .
TRANSPLANTATION, 1988, 45 (06) :1091-1094
[6]   THE PREDICTIVE VALUE OF HLA-DR OLIGOTYPING FOR MLC RESPONSES [J].
BAXTERLOWE, LA ;
ECKELS, DD ;
ASH, R ;
CASPER, J ;
HUNTER, JB ;
GORSKI, J .
TRANSPLANTATION, 1992, 53 (06) :1352-1357
[7]  
BAXTERLOWE LA, 1991, TRANSPLANT P, V23, P1699
[8]  
BAXTERLOWE LA, 1995, TRANSPLANT P, V27, P1377
[9]   MARROW TRANSPLANTATION FROM RELATED DONORS OTHER THAN HLA-IDENTICAL SIBLINGS [J].
BEATTY, PG ;
CLIFT, RA ;
MICKELSON, EM ;
NISPEROS, BB ;
FLOURNOY, N ;
MARTIN, PJ ;
SANDERS, JE ;
STEWART, P ;
BUCKNER, CD ;
STORB, R ;
THOMAS, ED ;
HANSEN, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 313 (13) :765-771
[10]   MARROW TRANSPLANTATION FROM HLA-MATCHED UNRELATED DONORS FOR TREATMENT OF HEMATOLOGIC MALIGNANCIES [J].
BEATTY, PG ;
HANSEN, JA ;
LONGTON, GM ;
THOMAS, ED ;
SANDERS, JE ;
MARTIN, PJ ;
BEARMAN, SI ;
ANASETTI, C ;
PETERSDORF, EW ;
MICKELSON, EM ;
PEPE, MS ;
APPELBAUM, FR ;
BUCKNER, CD ;
CLIFT, RA ;
PETERSEN, FB ;
STEWART, PS ;
STORB, RF ;
SULLIVAN, KM ;
TESLER, MC ;
WITHERSPOON, RP .
TRANSPLANTATION, 1991, 51 (02) :443-447